Nusano and GlyTherix Announce Lutetium-177 Supply Agreement

1 year ago

VALENCIA, Calif. and SYDNEY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of radioisotopes, and…

Universe Pharmaceuticals INC Announces $15 Million Registered Direct Offering

1 year ago

Jiangxi, China, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (Nasdaq: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical…

Orchestra BioMed Announces AVIM Therapy Program Presentations at ICI Meeting

1 year ago

NEW HOPE, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”),…

Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer

1 year ago

MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company…

Vittoria Biotherapeutics Presents Positive Preclinical Data at 66th Annual ASH Meeting Supporting its Novel Approach to Engineered CAR-T Cell Therapies

1 year ago

Data further validates the Company’s proprietary Senza5™ technology platform to engineer enabled CAR-T cell therapies PHILADELPHIA, Dec. 09, 2024 (GLOBE NEWSWIRE)…

MEDIROM Healthcare Technologies Has Received Orders for Over 25,000 MOTHER Bracelet Units

1 year ago

TOKYO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) announces that its subsidiary MEDIROM MOTHER…

Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers

1 year ago

Planegg/Martinsried, December 9, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on…

Nikon and eLabNext collaborate to integrate the NIS-Elements imaging platform with eLabNext’s Digital Lab Platform in the US

1 year ago

FRAMINGHAM, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Nikon and eLabNext partner to enhance data integration between NIS-Elements imaging software…

DARZALEX® (daratumumab) SC-based regimens improve MRD negativity and progression-free survival in newly diagnosed multiple myeloma, and overall survival in AL amyloidosis

1 year ago

New analysis from Phase 3 CEPHEUS study demonstrates 85 percent of patients who achieved MRD negativity (10-6) with daratumumab SC…

Scryb Announces Sale of its Joint Venture Interest in Fionet Rapid Response Group for CAD$3.5 million plus a Royalty

1 year ago

Toronto, Ontario--(Newsfile Corp. - December 9, 2024) - Scryb Inc.  (CSE: SCYB) (OTCQB: SCYRF) (FSE: EIY) ("Scryb'' or the "Company") is pleased to…